633 related articles for article (PubMed ID: 26316345)
1. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
Kongnakorn T; Lanitis T; Lieven A; Thijs V; Marbaix S
Clin Drug Investig; 2014 Oct; 34(10):709-21. PubMed ID: 25164005
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
5. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
10. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
Ademi Z; Pasupathi K; Liew D
Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
14. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective.
Ademi Z; Pasupathi K; Liew D
Appl Health Econ Health Policy; 2017 Jun; 15(3):363-374. PubMed ID: 27699648
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].
Escolar-Albaladejo G; Barón-Esquivias G; Zamorano JL; Betegón-Nicolás L; Canal-Fontcuberta C; de Salas-Cansado M; Rubio-Rodríguez D; Rubio-Terrés C
Aten Primaria; 2016; 48(6):394-405. PubMed ID: 26832316
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
Altawalbeh SM; Alshogran OY; Smith KJ
Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
[TBL] [Abstract][Full Text] [Related]
19. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Shah A; Shewale A; Hayes CJ; Martin BC
Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]